AU2018206564B2 - Medicinal compounds and nutritional supplements - Google Patents

Medicinal compounds and nutritional supplements Download PDF

Info

Publication number
AU2018206564B2
AU2018206564B2 AU2018206564A AU2018206564A AU2018206564B2 AU 2018206564 B2 AU2018206564 B2 AU 2018206564B2 AU 2018206564 A AU2018206564 A AU 2018206564A AU 2018206564 A AU2018206564 A AU 2018206564A AU 2018206564 B2 AU2018206564 B2 AU 2018206564B2
Authority
AU
Australia
Prior art keywords
alkyl
group
substituted
formula
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018206564A
Other languages
English (en)
Other versions
AU2018206564A1 (en
Inventor
Andrea Leone-Bay
Gregory WESNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spoke Sciences Inc
Original Assignee
Spoke Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62790943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018206564(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Spoke Sciences Inc filed Critical Spoke Sciences Inc
Publication of AU2018206564A1 publication Critical patent/AU2018206564A1/en
Assigned to SPOKE SCIENCES, INC. reassignment SPOKE SCIENCES, INC. Request for Assignment Assignors: RECEPTOR HOLDINGS, INC.
Application granted granted Critical
Publication of AU2018206564B2 publication Critical patent/AU2018206564B2/en
Priority to AU2024201078A priority Critical patent/AU2024201078A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2018206564A 2017-01-03 2018-01-03 Medicinal compounds and nutritional supplements Active AU2018206564B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201078A AU2024201078A1 (en) 2017-01-03 2024-02-20 Medicinal compounds and nutritional supplements

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762441908P 2017-01-03 2017-01-03
US62/441,908 2017-01-03
PCT/US2018/012261 WO2018129097A1 (en) 2017-01-03 2018-01-03 Medicinal compounds and nutritional supplements

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201078A Division AU2024201078A1 (en) 2017-01-03 2024-02-20 Medicinal compounds and nutritional supplements

Publications (2)

Publication Number Publication Date
AU2018206564A1 AU2018206564A1 (en) 2019-08-15
AU2018206564B2 true AU2018206564B2 (en) 2023-12-07

Family

ID=62790943

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018206564A Active AU2018206564B2 (en) 2017-01-03 2018-01-03 Medicinal compounds and nutritional supplements
AU2024201078A Pending AU2024201078A1 (en) 2017-01-03 2024-02-20 Medicinal compounds and nutritional supplements

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201078A Pending AU2024201078A1 (en) 2017-01-03 2024-02-20 Medicinal compounds and nutritional supplements

Country Status (14)

Country Link
US (2) US20190336472A1 (https=)
EP (1) EP3565539A4 (https=)
JP (3) JP7281815B2 (https=)
KR (1) KR20190103302A (https=)
CN (1) CN110121337A (https=)
AU (2) AU2018206564B2 (https=)
BR (1) BR112019013743A2 (https=)
CA (1) CA3049226A1 (https=)
CL (1) CL2019001832A1 (https=)
CO (1) CO2019008176A2 (https=)
EA (1) EA201991641A1 (https=)
IL (1) IL267831A (https=)
MX (1) MX2019007968A (https=)
WO (1) WO2018129097A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180781B2 (en) * 2016-08-21 2021-11-23 Insectergy, Llc Biosynthetic cannabinoid production methods
EP3928776B1 (en) 2016-04-22 2025-11-12 Spoke Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
KR20190103302A (ko) * 2017-01-03 2019-09-04 리셉터 홀딩스, 인크. 의약 화합물 및 영양 보충제
WO2019144221A1 (en) * 2018-01-29 2019-08-01 Solantech Inc. Methods of treating and/or preventing bedsores using nabilone
KR20210116432A (ko) * 2018-10-10 2021-09-27 틸레이, 인크. 화학요법으로 유발된 메스꺼움 및 구토 치료를 위한 방법 및 제형
AU2019385420A1 (en) * 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
EP3946262B1 (en) 2019-08-30 2024-07-31 Evie Sa Loaded granules, their process of production and their uses
JP2023505351A (ja) 2019-12-09 2023-02-08 ニコベンチャーズ トレーディング リミテッド 口腔用組成物のための薬剤
US12171872B2 (en) 2019-12-09 2024-12-24 Nicoventures Trading Limited Oral compositions and methods of manufacture
CN113040337B (zh) * 2021-04-22 2022-12-09 四川大学 一种熏肉制品及其制备方法
WO2024253228A1 (ko) * 2023-06-09 2024-12-12 주식회사 메타파인즈 악액질 및 근손실의 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130224300A1 (en) * 2011-08-26 2013-08-29 Edward T. Maggio Compositions and methods thereof for oral administration of drugs
US20130295026A1 (en) * 2010-11-25 2013-11-07 Aop Orphan Pharmaceuticals Ag Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin
WO2015131269A1 (en) * 2014-03-04 2015-09-11 Pharmascience Inc. Orally disintegrating tablet of nabilone comprising mannitol-based granules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523221A (ja) 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
AU2002352974A1 (en) * 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
US9308175B2 (en) 2006-09-15 2016-04-12 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
EP3928776B1 (en) 2016-04-22 2025-11-12 Spoke Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
KR20190103302A (ko) 2017-01-03 2019-09-04 리셉터 홀딩스, 인크. 의약 화합물 및 영양 보충제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130295026A1 (en) * 2010-11-25 2013-11-07 Aop Orphan Pharmaceuticals Ag Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin
US20130224300A1 (en) * 2011-08-26 2013-08-29 Edward T. Maggio Compositions and methods thereof for oral administration of drugs
WO2015131269A1 (en) * 2014-03-04 2015-09-11 Pharmascience Inc. Orally disintegrating tablet of nabilone comprising mannitol-based granules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 25, JPN6021040226, 2005, pages 307 - 312, ISSN: 0004618045 *

Also Published As

Publication number Publication date
JP7281815B2 (ja) 2023-05-26
CL2019001832A1 (es) 2020-01-31
EP3565539A4 (en) 2020-08-12
CO2019008176A2 (es) 2019-08-20
US20230293479A1 (en) 2023-09-21
EA201991641A1 (ru) 2020-03-10
CN110121337A (zh) 2019-08-13
IL267831A (en) 2019-09-26
MX2019007968A (es) 2019-12-05
JP7466238B2 (ja) 2024-04-12
JP2020503357A (ja) 2020-01-30
KR20190103302A (ko) 2019-09-04
US20190336472A1 (en) 2019-11-07
BR112019013743A2 (pt) 2020-01-21
AU2018206564A1 (en) 2019-08-15
CA3049226A1 (en) 2018-07-12
WO2018129097A1 (en) 2018-07-12
JP2024075724A (ja) 2024-06-04
EP3565539A1 (en) 2019-11-13
AU2024201078A1 (en) 2024-03-07
JP2023071697A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
AU2022201021B2 (en) Fast-acting plant-based medicinal compounds and nutritional supplements
AU2018206564B2 (en) Medicinal compounds and nutritional supplements
US20250120939A1 (en) Fast-acting plant-based medicinal compounds and nutritional supplements
AU2024219599A1 (en) Herbal compositions with improved bioavailability
US12303487B2 (en) N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SPOKE SCIENCES, INC.

Free format text: FORMER APPLICANT(S): RECEPTOR HOLDINGS, INC.

FGA Letters patent sealed or granted (standard patent)